Maartje G. Noordhuis

Maartje G. Noordhuis

Auto-generated profile, based on publicly available information

Maartje G. Noordhuis

Dept. of Otorhinolaryngology/Head and Neck Surgery, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 April 2020 in Clinical Otolaryngology
Verified
Journal Article
Open access
PDF file
MNMaartje G. Noordhuis
Maartje G. Noordhuis
EKEmiel A. Kop
Emiel A. Kop
BVBert van der Vegt
Bert van der Vegt
HLHans Langendijk
Hans Langendijk
BLBernard F.A.M. van der Laan
Bernard F.A.M. van der Laan
GBGeertruida de Bock
Geertruida de Bock
Background: The choice of treatment in laryngeal cancer is mainly based on tumor stage, post‐treatment morbidity and quality of life. Biological tumor markers might also be of potential clinical relevance.Objective of the review: The aim was to systematically review the value of published biological tumor markers to predict local control in laryngeal cancer patients treated with definitive radiotherapy.Type of Review: Systematic review.Search strategy: PubMed, Embase, Cochrane Library.Evaluation Method: A literature search was performed using multiple terms for laryngeal cancer, radiotherapy, biological markers, detection methods and local control or survival. Studies regarding the relation between biological tumor markers and local control or survival in laryngeal cancer patients primarily treated with radiotherapy were included. Markers were clustered on biological function. Quality of all studies was assessed. Study selection, data extraction and quality assessment was performed by two independent reviewers.Results: A total of 52 studies out of 618 manuscripts, concerning 118 markers, were included. EGFR and P53 showed consistent evidence for not being predictive of local control after primary radiotherapy, whereas proliferation markers (ie high Ki‐67 expression) showed some, but no consistent, evidence for being predictive of better local control. Other clusters of markers (markers involved in angiogenesis and hypoxia, apoptosis markers, cell cycle, COX‐2 and DNA characteristics) showed no consistent evidence towards being predictors of local control after primary radiotherapy.Conclusions: Cell proliferation could be of potential interest for predicting local control after primary radiotherapy in laryngeal cancer patients, whereas EGFR and p53 are not predictive in contrast to some previous analyses. Large diversity in research methods is found between studies, which results in contradictory outcomes. Future studies need to be more standardised and well described according to the REMARK criteria in order to have better insight into which biomarkers can be used as predictors of local control after primary radiotherapy.

27 September 2019 in Clinical Otolaryngology
Verified
Journal Article
Open access
PDF file
EKEmiel Kop
Emiel Kop
GBGeertruida de Bock
Geertruida de Bock
MNMaartje G. Noordhuis
Maartje G. Noordhuis
LSLorian Slagter-Menkema
Lorian Slagter-Menkema
BLBernard F.A.M. van der Laan
Bernard F.A.M. van der Laan
BVBert van der Vegt
Bert van der Vegt
Objectives: Ambiguous results have been reported on the predictive value of the Ki‐67 proliferation index (Ki‐67 PI) regarding local control (LC) and survival after primary radiotherapy (RT) in early‐stage laryngeal squamous cell cancer (LSCC). Small study size, heterogenic inclusion, variations in immunostaining and cut‐off values are attributing factors. Our aim was to elucidate the predictive value of the Ki‐67 PI for LC and disease‐specific survival (DSS) using a well‐defined series of T1‐T2 LSCC, standardised automatic immunostaining and digital image analysis (DIA).Methods: A consecutive and well‐defined cohort of 208 patients with T1‐T2 LSCC treated with primary RT was selected. The Ki‐67 PI was determined using DIA. Mann‐Whitney U‐tests, logistic and Cox regression analyses were performed to assess associations between Ki‐67 PI, clinicopathological variables, LC and DSS.Results: In multivariate Cox regression analysis, poor tumour differentiation (HR 2.20; 95% CI 1.06‐4.59, P = .04) and alcohol use (HR 2.84, 95% CI 1.20‐6.71; P = .02) were independent predictors for LC. Lymph node positivity was an independent predictor for DSS (HR 3.16, 95% CI 1.16‐8.64; P = .03). Ki‐67 PI was not associated with LC (HR 1.59; 95% CI 0.89‐2.81; P = .11) or DSS (HR 0.98; 95% CI 0.57‐1.66; P = .97). In addition, continuous Ki‐67 PI was not associated with LC (HR 2.03; 95% CI 0.37‐11.14, P = .42) or DSS (HR 0.62; 95% CI 0.05‐8.28; P = .72).Conclusion: The Ki‐67 PI was not found to be a predictor for LC or DSS and therefore should not be incorporated in treatment‐related decision‐making for LSCC.